# RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

> **NCT05943379** · PHASE2 · RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 85 (estimated)

## Conditions studied

- NMIBC

## Interventions

- **DRUG:** RC48-ADC in Combination with gemcitabine

## Key facts

- **NCT ID:** NCT05943379
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-08
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2023-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05943379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05943379, "RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05943379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*